Real-World Prevalence of BTK Mutations in Patients with CLL - Drs. Jennifer Woyach and Alan Skarbnik

33 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
In patients being treated with BTK inhibitors, mutations in BTK are relatively rare (2 in 100 patients). When patients do develop mutations, it most commonly occurs at the binding site of covalent BTK inhibitors.

Dr. Alan Skarbnik from Novant Health Cancer Institute and colleagues presented the results at the American Society for Hematology (ASH) Annual Meeting in 2024.

Read the full article on CLL Society's website at: https://cllsociety.org/2025/08/real-world-prevalence-of-btk-mutations-in-patients-with-cll/
__________________________________________________________________________________________
CLL Society Website: https://cllsociety.org/
Facebook: https://www.facebook.com/CLLsociety
Twitter: https://twitter.com/CllSociety
LinkedIn: https://www.linkedin.com/company/cll-society/
Categoria
Oncology
Commenta per primo questo video.

Prossimo